Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tunlametinib + PD-1 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Shanghai KeChow Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (tunlametinib), Intravenous (PD-1 Monoclonal Antibody)[1][2][8]
01
Overview
A combination of **tunlametinib**, a selective and potent MEK1/2 inhibitor developed for cancers with RAS/RAF mutations, and a **PD-1 monoclonal antibody** (immune checkpoint inhibitor), used in investigational settings for the treatment of cancers such as NRAS-mutant advanced melanoma and thyroid cancer. Tunlametinib targets the MAPK signaling pathway, while PD-1 monoclonal antibodies block the PD-1/PD-L1 interaction, thereby enhancing anti-tumor immune responses. The combination leverages the tumor-intrinsic cytostatic/cytotoxic mechanism of MEK inhibition with the immune-mediated tumor clearance promoted by PD-1 blockade. This combination is currently being evaluated in clinical trials[1][5][7][9].
- Brand names
- None known (for the combination)None identified for tunlametinib as a marketed brand
- Other names
- Tunlametinib + PD-1 mAb
02
Targets
MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)PDCD1 (Programmed cell death protein 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on tunlametinib + PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tunlametinib + PD-1 monoclonal antibody.